Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database

被引:3
|
作者
Liu, Leping [1 ]
Zheng, Hong [2 ]
Chen, Shanshan [3 ]
Wang, Shengfeng [4 ,5 ,6 ]
Yang, Minghua [1 ,6 ,7 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pediat, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Pharm, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, MOE Key Lab Rare Pediat Dis, Changsha, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Hunan Clin Res Ctr Pediat Canc, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
low-molecular-weight heparin; heparin-induced thrombocytopenia; characteristics; treatments; pharmacovigilance; ENOXAPARIN-INDUCED THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; SKIN NECROSIS; PATIENT; RIVAROXABAN; MANAGEMENT; THROMBOSIS; ARTERIAL; FONDAPARINUX;
D O I
10.3389/fphar.2023.1247253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used anticoagulants for the management of arterial and venous thromboses. However, it is crucial to be aware that LMWH can, in rare cases, lead to a dangerous complication known as heparin-induced thrombocytopenia (HIT). The objective of this study was to evaluate the pharmacovigilance and clinical features of HIT associated with LMWH, as well as identify treatment strategies and risk factors to facilitate prompt management.Methods: We extracted adverse event report data from the FDA Adverse Event Reporting System (FAERS) database for pharmacovigilance assessment. Case reports on LMWH-induced thrombocytopenia dated up to 20 March 2023 were collected for retrospective analysis.Results: Significantly elevated reporting rates of HIT were shown in adverse event (AE) data of LMWHs in the FAERS database, while tinzaparin had a higher proportional reporting ratio (PRR) and reporting odds ratio (ROR) than other LMWHs, indicating a greater likelihood of HIT. Case report analysis indicated that a total of 43 patients showed evidence of LMWH-induced thrombocytopenia with a median onset time of 8 days. Almost half of the events were caused by enoxaparin. LMWHs were mainly prescribed for the treatment of embolism and thromboprophylaxis of joint operation. Patients with a history of diabetes or surgery appeared to be more susceptible to HIT. Clinical symptoms were mostly presented as thrombus, skin lesion, and dyspnea. Almost 90% of the patients experienced a platelet reduction of more than 50% and had a Warkentin 4T score of more than 6, indicating a high likelihood of HIT. In all patients, LMWHs that were determined to be the cause were promptly withdrawn. Following the discontinuation of LMWHs, almost all patients were given alternative anticoagulants and eventually achieved recovery.Conclusion: LMWH-induced thrombocytopenia is rare but serious, with increased risk in patients with diabetes or a surgical history. Prompt recognition and management are crucial for the safe use of LMWHs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] HEPARIN-INDUCED THROMBOSIS AND THROMBOCYTOPENIA - TREATMENT WITH A LOW-MOLECULAR WEIGHT HEPARIN
    CONDOURET, J
    LASSOUED, S
    ROQUES, CF
    BIERME, R
    BISMUTH, M
    PUJOL, M
    PRESSE MEDICALE, 1984, 13 (40): : 2455 - 2455
  • [32] Low-molecular-weight heparin-induced skin necrosis
    Füreder, W
    Kyrle, PA
    Gisslinger, H
    Lechner, K
    ANNALS OF HEMATOLOGY, 1998, 77 (03) : 127 - 130
  • [33] Low-molecular-weight heparin-induced skin necrosis
    W. Füreder
    P. A. Kyrle
    H. Gisslinger
    K. Lechner
    Annals of Hematology, 1998, 77 : 127 - 130
  • [34] Heparin-induced thrombocytopenia after switching from unfractionated heparin to low-molecular-weight heparin: A case report and literature review
    Zhang, Fan
    Yang, Yiya
    Li, Lizhen
    Zhang, Li
    Wu, Ying
    Liang, Yumei
    Luo, Xun
    CLINICAL NEPHROLOGY, 2023, 100 (01) : 37 - 40
  • [35] SUCCESSFUL ADMINISTRATION OF LOW-MOLECULAR-WEIGHT HEPARIN IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA AND COUMARIN-INDUCED SKIN NECROSIS
    DRAKOS, P
    UZIELY, B
    NAGLER, A
    GILLIS, S
    ELDOR, A
    HAEMOSTASIS, 1993, 23 (05) : 259 - 262
  • [36] So, does low-molecular-weight heaprin cause less heparin-induced thrombocytopenia than unfractionated heparin or not?
    Warkentin, Theodore E.
    Greinacher, Andreas
    CHEST, 2007, 132 (04) : 1108 - 1110
  • [37] The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study
    Prandoni, P
    Siragusa, S
    Girolami, B
    Fabris, F
    BLOOD, 2005, 106 (09) : 3049 - 3054
  • [38] Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia
    Gleichgerrcht, Ezequiel
    Lim, Ming Y.
    Turan, Tanya N.
    NEUROLOGIST, 2017, 22 (06) : 241 - 244
  • [39] LOW-MOLECULAR-WEIGHT HEPARIN-INDUCED SKIN NECROSIS: ABOUT 2 CASES
    Yombi, J. C.
    Belkhir, L.
    De Baere, T.
    Dubuc, J. E.
    Hainaut, P.
    ACTA CLINICA BELGICA, 2009, 64 (03) : 228 - 230
  • [40] Antibodies to platelet factor 4 - Heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin - Clinical implications for heparin-induced thrombocytopenia
    Pouplard, C
    May, MA
    Iochmann, S
    Amiral, J
    Vissac, AM
    Marchand, M
    Gruel, Y
    CIRCULATION, 1999, 99 (19) : 2530 - 2536